Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR-1701 in Combination With Radiotherapy and Chemotherapy as Perioperative Treatment for Resectable Locally Advanced Rectal Cancer, an Open Label, Single-arm, Multicenter Phase II Trial

NCT05300269 is registered in ClinicalTrials.gov with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT05300269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05300269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR-1701 in Combination With Radiotherapy and Chemotherapy as Perioperative Treatment for Resectable Locally Advanced Rectal Cancer, an Open Label, Single-arm, Multicenter Phase II Trial
Lead sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
July 5, 2022
Completion date
October 31, 2026
Enrollment
73 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal cancer